華森製藥(002907.SZ)：獨家中成藥產品八味芪龍顆粒進入國家醫保目錄
格隆匯11月28日丨華森製藥(002907.SZ)公佈，2019年11月28日，國家醫療保障局、人力資源社會保障部發布了《關於將2019年談判藥品納入
<國家基本醫療保險、工傷保險和生育保險藥品目錄>
乙類範圍的通知》(醫保發〔2019〕65號)，公司生產的獨家中成藥產品八味芪龍顆粒經過前期價格談判成功進入《國家基本醫療保險、工傷保險和生育保險藥品目錄》(“《國家醫保目錄》(2019年版)”)乙類範圍。此前，公司獨家中成藥品種六味安神膠囊成功進入《國家醫保目錄》(2019年版)常規目錄。因此，公司有2個獨家中成藥品種成功新增進入《國家醫保目錄》(2019年版)。連同繼續保留在《國家醫保目錄》(2019年版)中的3個獨家中成藥品種都樑軟膠囊、甘桔冰梅片、痛瀉寧顆粒，至此，華森製藥共計5個獨家中成藥品種入選《國家醫保目錄》(2019年版)。
截至公告日，公司共取得藥品批准文號69個，其中入選《國家醫保目錄》(2019年版)的品規51個(含本年度新進品規3個——八味芪龍顆粒、六味安神膠囊和《國家基藥目錄》品種鹽酸戊乙奎醚注射液)。
八味芪龍顆粒於2013年由國家食品藥品監督管理總局批准上市。該產品為全國獨家品種，獲得國家發明專利，是治療中風病中經絡(腦梗塞)的首選藥物。藥品名稱：八味芪龍顆粒；適應症或功能主治：補氣活血，通經活絡。用於中風病中經絡(輕中度腦梗塞)恢復期氣虛血瘀證，症見半身不遂、言語謇澀、面色晃白，氣短乏力，舌質暗淡，或有瘀斑瘀點，或有齒痕，苔白或白膩，脈沉細或細澀等。所屬藥品註冊分類及編號：乙類/10；是否屬於處方藥：是；支付標準：2.93元(6g/袋)。
腦梗塞又稱缺血性腦卒中，是指因腦部血液供應障礙，缺血、缺氧所導致的侷限性腦組織的缺血性壞死或軟化。根據PDB數據庫顯示，2018年國內腦血管病用藥市場約91.74億元(未放大)，並且伴隨人口老齡化的加快發病率不斷攀升，市場規模將進一步增大。隨着八味芪龍顆粒進入《國家醫保目錄》(2019年版)乙類範圍，其市場佔有率將有望進一步快速提升。
八味芪龍顆粒為公司心腦血管類的重要產品，此次進入《國家醫保目錄》(2019年版)乙類範圍，可使更多腦梗塞患者獲益，並有望擴大產品的市場份額，對公司的經營業績產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
